Literature DB >> 16084940

Poly(adenosine diphosphate-ribose) polymerase 1 expression in malignant melanomas from photoexposed areas of the head and neck region.

Stefania Staibano1, Stefano Pepe, Lorenzo Lo Muzio, Pasquale Somma, Massimo Mascolo, Giuseppe Argenziano, Massimiliano Scalvenzi, Gaetano Salvatore, Gabriella Fabbrocini, Guido Molea, Angelo Raffaele Bianco, Chiara Carlomagno, Gaetano De Rosa.   

Abstract

The family of the poly(adenosine diphosphate-ribose) polymerase (PARP) proteins is directly involved in genomic stability, DNA repair, and apoptosis by DNA damage. In this study, we evaluated the role of PARP-1 in melanoma and its prognostic importance. We studied by immunohistochemistry and Western blot analysis PARP-1 expression in a selected series of 80 primary melanoma of the head and neck region. The results were correlated with tumor thickness and patient's outcome. A follow-up of at least 3 years was available. Fifteen cases of benign melanocytic nevi were used as controls. Normal melanocytes showed only scattered, focal nuclear positivity and were considered as negative for PARP-1 expression by immunohistochemistry (score, 0). Thirty cases of melanoma (37.5%) showed nuclear expression of PARP-1 in both radial and vertical growth phases. Western blot analysis showed the presence of a high signal for full-length PARP-1 only in the cases with high immunohistochemical (nuclear) expression of protein (score, ++/+++) in both radial and vertical growth phase. A significant correlation was present between PARP-1 expression in vertical growth phase and the thickness of tumor lesion (P = .014); all but one tumor measuring less than 0.75 mm showed no or low PARP-1 expression. No correlation was found between PARP-1 expression in radial growth phase and tumor thickness (P = .38, data not shown). These data suggest that PARP-1 overexpression is a potential novel molecular marker of aggressive cutaneous malignant melanoma and a direct correlation between PARP-1-mediated inhibition of the apoptosis and biologic behavior of cutaneous malignant melanoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16084940     DOI: 10.1016/j.humpath.2005.04.017

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  37 in total

1.  Association between PARP-1 V762A polymorphism and cancer susceptibility: a meta-analysis.

Authors:  Hongping Yu; Hongxia Ma; Ming Yin; Qingyi Wei
Journal:  Genet Epidemiol       Date:  2011-11-29       Impact factor: 2.135

2.  Biomarker-Based PET Imaging of Diffuse Intrinsic Pontine Glioma in Mouse Models.

Authors:  Susanne Kossatz; Brandon Carney; Melanie Schweitzer; Giuseppe Carlucci; Vesselin Z Miloushev; Uday B Maachani; Prajwal Rajappa; Kayvan R Keshari; David Pisapia; Wolfgang A Weber; Mark M Souweidane; Thomas Reiner
Journal:  Cancer Res       Date:  2017-01-20       Impact factor: 12.701

Review 3.  Trial watch - inhibiting PARP enzymes for anticancer therapy.

Authors:  Antonella Sistigu; Gwenola Manic; Florine Obrist; Ilio Vitale
Journal:  Mol Cell Oncol       Date:  2015-06-10

4.  Expression of BAG-1 and PARP-1 in precursor lesions and invasive cervical cancer associated with human papillomavirus (HPV).

Authors:  Marcela Kazue Hassumi-Fukasawa; Fabiana Alves Miranda-Camargo; Bruna Riedo Zanetti; Denise Faria Galano; Alfredo Ribeiro-Silva; Edson Garcia Soares
Journal:  Pathol Oncol Res       Date:  2012-03-28       Impact factor: 3.201

Review 5.  Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality.

Authors:  Mary Leung; David Rosen; Scott Fields; Alessandra Cesano; Daniel R Budman
Journal:  Mol Med       Date:  2011-03-11       Impact factor: 6.354

6.  Initial evaluation of Cu-64 labeled PARPi-DOTA PET imaging in mice with mesothelioma.

Authors:  Tao Huang; Pengcheng Hu; Anna B Banizs; Jiang He
Journal:  Bioorg Med Chem Lett       Date:  2017-05-26       Impact factor: 2.823

7.  Non-invasive PET Imaging of PARP1 Expression in Glioblastoma Models.

Authors:  Brandon Carney; Giuseppe Carlucci; Beatriz Salinas; Valentina Di Gialleonardo; Susanne Kossatz; Axel Vansteene; Valerie A Longo; Alexander Bolaender; Gabriela Chiosis; Kayvan R Keshari; Wolfgang A Weber; Thomas Reiner
Journal:  Mol Imaging Biol       Date:  2016-06       Impact factor: 3.488

8.  Overexpression of Chromatin Assembly Factor-1/p60 helps to predict the prognosis of melanoma patients.

Authors:  Massimo Mascolo; Maria Luisa Vecchione; Gennaro Ilardi; Massimiliano Scalvenzi; Guido Molea; Maria Di Benedetto; Loredana Nugnes; Maria Siano; Gaetano De Rosa; Stefania Staibano
Journal:  BMC Cancer       Date:  2010-02-24       Impact factor: 4.430

9.  Dimethylfumarate inhibits melanoma cell proliferation via p21 and p53 induction and bcl-2 and cyclin B1 downregulation.

Authors:  Irina Kaluzki; Igor Hrgovic; Tsige Hailemariam-Jahn; Monika Doll; Johannes Kleemann; Eva Maria Valesky; Stefan Kippenberger; Roland Kaufmann; Nadja Zoeller; Markus Meissner
Journal:  Tumour Biol       Date:  2016-07-29

10.  Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.

Authors:  Ruth Plummer; Christopher Jones; Mark Middleton; Richard Wilson; Jeffrey Evans; Anna Olsen; Nicola Curtin; Alan Boddy; Peter McHugh; David Newell; Adrian Harris; Patrick Johnson; Heidi Steinfeldt; Raz Dewji; Diane Wang; Lesley Robson; Hilary Calvert
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.